ERBB2 and breast carcinoma: Noh et al. [13] found a significant prognostic value of NLR in luminal subtype breast cancer (ER+ or PR+, HER2−), whereas Yao et al. [16] found that NLR has a significant prognostic value regardless of luminal type or TNBC.